Syndax price target lowered to $41 from $42 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Syndax to $41 from $42 and keeps a Buy rating on the shares. Syndax recently announced the closing of its previously announced public offering of 12,432,431 shares of its common stock, and it received approximately $230M in gross proceeds, the analyst tells investors in a research note. Syndax has several important upcoming catalysts, including for revumenib and axatilimab, the firm notes.